Today: 19 May 2026
Browse Category

NASDAQ:RXRX 8 October 2025 - 19 May 2026

Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

Recursion Pharmaceuticals shares fell 2.2% to $2.825 Tuesday, hitting a 52-week low of $2.77, after reporting first-quarter revenue of $6.47 million, down from $14.75 million a year earlier. Net loss narrowed to $117.5 million. Early clinical data for REC-1245 showed no dose-limiting toxicities in 16 solid-tumor patients. The company ended March with $665.2 million in cash.
19 May 2026
·
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
1 May 2026
··
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Recursion Pharmaceuticals shares rose 4.4% to $4.87 Monday after an updated investor presentation showed $755 million in cash at year-end 2025 and a projected runway through 2027. The company reported a 43% median reduction in polyp burden for its lead drug REC-4881 in a small trial, with mostly mild to moderate side effects. Recursion will present at the J.P. Morgan Healthcare Conference Tuesday.
12 January 2026
··
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals shares traded near $4.37 on December 24, 2025, after J.P. Morgan upgraded the stock and Cathie Wood’s ARK funds increased their position. Trading volume was in the low millions during the early-close Christmas Eve session. The moves follow positive clinical data from REC-4881’s Phase 1b/2 trial in FAP. RXRX’s market cap stands at roughly $2.12 billion.
24 December 2025
·
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals (RXRX) closed at $4.26 on December 19, 2025, with a market cap of about $2.1 billion after releasing Phase 1b/2 data for REC‑4881 in familial adenomatous polyposis. The trial showed a median 43% reduction in polyp burden at 13 weeks and 53% at 25 weeks. REC‑4881 has Fast Track and Orphan Drug status from the FDA and EU. Trading volume was heavy, with sentiment split on commercialization prospects.
21 December 2025
···
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.
20 December 2025
···
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals shares jumped over 10% to $4.68 on December 18, 2025, after JPMorgan upgraded the stock to Overweight and raised its price target to $11. The upgrade followed positive clinical data for REC-4881 in familial adenomatous polyposis and cited potential U.S. peak sales above $1 billion. Trading volume surged to tens of millions of shares.
18 December 2025
··
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals reported Phase 1b/2 trial data showing its AI-discovered drug REC-4881 reduced polyp burden by a median 43% at 13 weeks in patients with familial adenomatous polyposis. Shares rose as much as 6% pre-market before settling in the mid-$4 range. Most patients maintained or improved reductions after stopping treatment. No approved drugs currently exist for this condition.
8 December 2025
···
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals shares closed at $4.71 on December 5, 2025, near the bottom of their 52-week range, with market cap at $2.46 billion. CEO Christopher Gibson and co-founder Blake Borgeson sold shares in early December. The company will present clinical data for its lead asset REC-4881 on December 8. Najat Khan is set to become CEO on January 1, 2026.
7 December 2025
·
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) closed Friday at $4.17, up 8.31%, with volume near 33 million shares and trading near its 52-week low. MarketBeat reports a consensus “Hold” rating, with a $7.25 average price target and Q3 revenue down 80% year-on-year. Kingsview Wealth Management increased its RXRX stake by over 500% in Q2. About 89% of shares are institutionally held.
24 November 2025
···
Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals shares fell 15% in the past week to around $5, down 55% from their 52-week high. Q3 2025 revenue missed estimates at $5 million, with net loss widening to $162.3 million. The company announced a $30 million milestone payment from Roche/Genentech and a CEO transition, with Najat Khan set to take over in January. Recursion holds about $785 million in cash, enough to fund operations through 2027.
5 November 2025
··
Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion Pharmaceuticals closed at $6.04 on Oct. 24, 2025, after volatile trading and a 44% monthly surge. Q2 revenue rose 33% to $19.2 million, but net loss reached $171.9 million as R&D spending climbed. The company completed a $630 million merger with Exscientia and reported $534 million cash on hand. Key drug candidates advanced in clinical trials, with several late-stage readouts expected by year-end.
26 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion Pharmaceuticals shares jumped over 16% to $6.80 intraday on Oct. 20, capping a volatile month that saw a 44% gain and heavy trading volume. CEO Chris Gibson sold 100,000 shares on Oct. 10 for about $604,000, drawing analyst scrutiny. The company reported a Q2 net loss of $171.9 million on $19.2 million revenue. Recursion recently acquired Exscientia in a $630 million all-stock deal.
20 October 2025
··
Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion Pharmaceuticals shares surged 16% on Oct 8 after its CEO spoke at an AI conference, then traded around $6.50 intraday on Oct 16 with volume spiking to 86.9 million shares. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, with $534 million in cash. Recursion focuses on oncology and rare disease drugs, recently acquiring Exscientia and licensing new assets.
16 October 2025
·
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion Pharmaceuticals’ stock jumped about 16% to $6.08 on Oct. 8, 2025, after renewed interest in its AI-driven drug discovery platform. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, ending the quarter with $534 million in cash. Management cut 20% of staff in mid-2025 to reduce costs. Analyst targets average $6.50, with mixed ratings.
15 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···

Stock Market Today

  • Institutional Firms and Insiders Reduce Alphabet Stock Holdings
    May 19, 2026, 2:26 PM EDT. Several institutional investors and corporate insiders have recently sold shares of Alphabet Inc., the parent company of Google, as revealed by SEC filings. These disclosures indicate a notable decline in equity holdings by major shareholders, which could signal concerns or portfolio rebalancing. Alphabet's stock performance may be influenced by this wave of selling amidst broader market dynamics.

Latest articles

Amazon Stock Drops, But the Bigger $200 Billion AI Question Isn’t Going Away

Amazon Stock Drops, But the Bigger $200 Billion AI Question Isn’t Going Away

19 May 2026
Amazon shares fell 2.3% to $258.73 Tuesday, underperforming the S&P 500 and Nasdaq as investors trimmed tech holdings ahead of Nvidia’s earnings. AWS revenue jumped 28% to $37.6 billion last quarter, but Amazon’s free cash flow dropped to $1.2 billion over the past year from $25.9 billion, reflecting heavy AI spending.
Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

19 May 2026
Astera Labs shares surged 15.2% to $248.36 Tuesday after Evercore ISI raised its price target and management highlighted rising AI data-center demand. CEO Jitendra Mohan said revenue grew from $65 million at its 2024 IPO to $308 million last quarter. The company’s market value neared $45 billion, with shares trading at about 168 times earnings. One customer accounted for over 70% of projected 2025 revenue.
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

19 May 2026
Recursion Pharmaceuticals shares fell 2.2% to $2.825 Tuesday, hitting a 52-week low of $2.77, after reporting first-quarter revenue of $6.47 million, down from $14.75 million a year earlier. Net loss narrowed to $117.5 million. Early clinical data for REC-1245 showed no dose-limiting toxicities in 16 solid-tumor patients. The company ended March with $665.2 million in cash.
Go toTop